FDA Tentatively Approves $40 Generic HIV Prevention Shot
Dr. Reddy's generic lenacapavir — the twice-yearly capsid inhibitor Gilead sells as Yeztugo — is expected to cost about $40 per person per year, against tens of thousands for the branded shot in the US. The license covers 120 countries. Doctors Without Borders counts 26 left out.
The drug works. The map of who can buy it is the argument.
A twice-a-year injection that nearly eliminates HIV acquisition risk just got a generic version priced at about $40 a year. [FDA approval of affordable generic HIV-prevention shot (Tutubi News)]
The FDA has granted tentative approval to Dr. Reddy's generic lenacapavir, the capsid inhibitor Gilead sells as Yeztugo. Tentative approval means the drug meets FDA standards but can't be sold in the United States yet — what it unlocks is procurement for 120 countries. [FDA approval of affordable generic HIV-prevention shot (Tutubi News)]
The mechanism is why two shots can replace a daily pill. Lenacapavir attacks the capsid — the protein shell around HIV's genetic material — and interferes with the virus at several stages of its life cycle, so protection doesn't depend on a patient's daily routine. In Gilead's PURPOSE 1 and PURPOSE 2 trials, the injection reduced the risk of acquiring HIV by approximately 96 to 100 percent among participants. Those are relative reductions, and they're the strongest prevention numbers the field has produced. [FDA approval of affordable generic HIV-prevention shot (Tutubi News)]
The economics are the announcement. The generic, developed by India's Dr. Reddy's Laboratories with support from Unitaid, the Clinton Health Access Initiative and South Africa's Wits Reproductive Health and HIV Institute, is expected to cost about $40 per person per year. The branded version — approved by the FDA in June 2025 — sells in the United States for tens of thousands of dollars a year. Gilead's licensing agreements cover 120 low- and middle-income countries; initial supplies are expected before the end of 2026, with broader availability in 2027. [FDA approval of affordable generic HIV-prevention shot (Tutubi News)]
The friction is in the map. Doctors Without Borders notes that 26 low- and middle-income countries remain excluded from the licensing arrangements — including countries in Latin America with growing HIV epidemics. And approval isn't delivery: each country still needs its own registration, supply chain and clinics able to give a twice-yearly injection on schedule. The distance between a $40 price and an administered dose is where this story will be decided. [FDA approval of affordable generic HIV-prevention shot (Tutubi News)]
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.